as 12-24-2024 4:00pm EST
Xeris Biopharma Holdings Inc is a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology. The company has three commercially available products, Gvoke, ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis, the first FDA-approved therapy for primary periodic paralysis, and Recorlev, approved by the FDA for the treatment of endogenous hypercortisolemia in adult patients with Cushing's Syndrome. The Company also has a pipeline of development programs to bring new products forward using its proprietary formulation science, XeriSol and XeriJect.
Founded: | 2005 | Country: | United States |
Employees: | N/A | City: | CHICAGO |
Market Cap: | 500.2M | IPO Year: | 2018 |
Target Price: | $4.87 | AVG Volume (30 days): | 1.8M |
Analyst Decision: | Buy | Number of Analysts: | 3 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -0.44 | EPS Growth: | N/A |
52 Week Low/High: | $1.69 - $3.87 | Next Earning Date: | 11-08-2024 |
Revenue: | $187,361,000 | Revenue Growth: | 22.72% |
Revenue Growth (this year): | 24.27% | Revenue Growth (next year): | 18.57% |
XERS Breaking Stock News: Dive into XERS Ticker-Specific Updates for Smart Investing
Business Wire
a month ago
Simply Wall St.
a month ago
MT Newswires
a month ago
GuruFocus.com
2 months ago
Zacks
2 months ago
Zacks
2 months ago
Associated Press Finance
2 months ago
Business Wire
2 months ago
The information presented on this page, "XERS Xeris Biopharma Holdings Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.